Targeted Radiation Therapy Resolves Dangerous Low Blood Sugar in 93% of Malignant Insulinoma Patients | Research

The takeaway

Peptide receptor radionuclide therapy (PRRT) resolved life-threatening hypoglycemia in 93% of malignant insulinoma patients, with median overall survival of 50 months.

93% hypoglycemia resolution
14 of 15 malignant insulinoma patients had their life-threatening low blood sugar resolved by targeted peptide radiation therapy

What the researchers found

PRRT with Lu-177 DOTATATE resolved hypoglycemia in 93% of patients (14/15) after a median of 2.5 months, with median overall survival of 50.1 months and successful re-treatment in all recurrence cases.

Why it matters

Malignant insulinoma is life-threatening primarily because of uncontrollable hypoglycemia. PRRT addresses both the tumor and the dangerous metabolic symptoms, providing a critical treatment option for patients who have exhausted other therapies.

The numbers in context

15 patients (7 female, median age 60). Median 7 cycles (range 1-15), median cumulative 42 GBq (range 4-117). 93% (14/15) had hypoglycemia resolution at median 2.5 months. Recurred in 7/14 at median 17.7 months. Recurrence group: more G3 (57% vs 0%), longer time to resolution (3.0 vs 0.5 months).

How the study worked

Retrospective review of 15 consecutive malignant insulinoma patients treated with PRRT at two Australian neuroendocrine tumor centers from 2004 to 2022.

Who was studied

Patients with malignant insulinoma and intractable hypoglycemia

What this study cannot tell us

Retrospective design, small sample size (n=15), single-arm without comparison group. Patient heterogeneity in tumor grade and treatment protocols. Hypoglycemia flare during treatment required hospitalization in nearly half of patients.

How to read the evidence

Retrospective case series — the strongest evidence feasible for a rare cancer. No randomized trials exist for this indication, making this one of the most informative datasets available.

When this study was published

Published in 2025, covering 18 years of clinical experience (2004-2022) at two specialized centers.

The bigger picture

This is one of the largest published cohorts of PRRT for malignant insulinoma. The results support PRRT as a viable treatment option for this rare but dangerous cancer, adding to the evidence base for peptide-targeted radiotherapy in neuroendocrine tumors.

Questions still open

Can earlier initiation of PRRT prevent the severe hypoglycemia episodes seen in higher-grade tumors?
Would combination with newer targeted agents improve progression-free survival beyond 18 months?

Common questions

What is PRRT and how does it treat insulinoma?

PRRT (peptide receptor radionuclide therapy) attaches radioactive material to a peptide that specifically targets tumor cell receptors. When injected, the peptide homes to the tumor and delivers targeted radiation directly to cancer cells, sparing most healthy tissue.

Did the low blood sugar come back after treatment?

In half of the patients who initially responded, hypoglycemia recurred after a median of about 18 months. However, re-treatment with PRRT was successful in all cases, providing continued disease control.

Read the original research

Peptide receptor radionuclide therapy in malignant insulinoma.

Endocrine-related cancer, 32(6)

View on PubMed ↗Publisher’s paper ↗

Citation

Pattison, David A; Kong, Grace; Akhurst, Timothy; Burge, Matthew; Chiang, Cherie; Hofman, Michael S; Hung, Te-Jui; Love, Amanda; Michael, Michael; Okano, Satomi; Ravi Kumar, Aravind S; Sachithanandan, Nirupa; Wyld, David; Hicks, Rodney J. (2025). Peptide receptor radionuclide therapy in malignant insulinoma.. Endocrine-related cancer, 32(6). https://doi.org/10.1530/ERC-25-0018